Venmax Drugs Boosts Capital by ₹4.20 Crore Via Warrant Conversion

Venmax Drugs and Pharmaceuticals Limited has converted 28 lakh warrants into equity shares, securing ₹4.20 crore. This move increases the company's paid-up capital to ₹11.58 crore.

The Filing: Warrant Conversion Details

On March 23, 2026, Venmax Drugs and Pharmaceuticals Limited announced the conversion of 28,00,000 warrants into equity shares. Each warrant was converted at an issue price of ₹20 per share, consisting of a ₹10 face value and a ₹10 premium. The conversion has infused ₹4.20 crore into the company's funds, raising its total paid-up capital to ₹11.58 crore.

Financial Impact

This capital infusion significantly strengthens Venmax Drugs' financial foundation. The additional funds can support operational expansion, research and development projects, or help manage existing obligations. It marks a positive development for the company's financial capacity and its potential market position.

Company Background

Venmax Drugs and Pharmaceuticals Ltd. operates in several business areas, including the manufacturing and sale of bulk drugs, pharmaceutical products, drug intermediates, and APIs, alongside IT & ITES services. The company is developing oncology products through R&D and plans to build a cGMP-compliant manufacturing unit in Hyderabad for export markets. Additionally, Venmax Drugs aims to establish a chain of medical stores named 'Ananya Pharma'. Historically, the company was incorporated as 'Yenkay Medico Private Limited', later changing its name to 'Yenkey Drugs & Pharmaceuticals Limited' before adopting its current name. On March 20, 2025, the company had issued 64,81,000 warrants at an exercise price of ₹20 each. Before the recent conversion, its paid-up capital was approximately ₹7.38 crore.

Key Changes and Impacts

The conversion of warrants adds 28 lakh new equity shares to the company's total outstanding count. This directly increases the paid-up capital by ₹4.20 crore, strengthening the company's equity base. The new funds are available to support business growth, R&D, or working capital requirements.

Potential Risks

A key risk for shareholders is the potential for substantial future dilution, as 36,81,000 warrants remain unconverted. Should these be exercised, existing shareholders' equity could be significantly impacted. It is also important to note past regulatory actions: SEBI previously initiated proceedings against Venmax Drugs and its directors concerning misrepresentation of financial statements, non-genuine transactions, misuse of company funds, and breach of fiduciary duties. These actions resulted in trading restrictions and a forensic audit. Furthermore, the company has recorded a negative Return on Equity (ROE) for three consecutive years and faces challenges with high debtor days, averaging 428 days.

Industry Peers

Venmax Drugs operates within the pharmaceutical sector, competing with larger companies like Sun Pharmaceutical Industries Ltd, Divi's Laboratories Ltd, and Laurus Labs Ltd. Sun Pharma stands as India's largest pharmaceutical company by revenue and a global generics player. Divi's Labs is recognized as a key manufacturer of Active Pharmaceutical Ingredients (APIs), while Laurus Labs is a significant entity in both APIs and formulations.

Key Metrics at a Glance

The company's paid-up capital trend shows an increase from approximately ₹7.38 crore in March 2025 to ₹11.58 crore in March 2026, driven by warrant conversions. Debtor days remain high at 428 days as of FY25, suggesting potential pressure on working capital.

Investor Watchlist

Investors will closely watch the conversion status of the remaining 36,81,000 outstanding warrants. The strategic deployment of the newly infused capital by the company will also be a key factor to observe. Future financial results will be essential for assessing the operational impact of the enhanced capital base and its effect on profitability.